Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.

WG, Cooksley; T, Piratvisuth; SD, Lee; V, Mahachai; YC, Chao; T, Tanwandee; A, Chutaputti; WY, Chang; FE, Zahm; N, Pluck

doi:10.1046/j.1365-2893.2003.00450.x

Public

Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.

Shared by NobleBlocks on Jul 1, 2003 • 12:00 AM UTC

Authors:

Cooksley WG

Piratvisuth T

Lee SD

Abstract

Current therapies for chronic hepatitis B (CHB) have a number of limitations, and better treatment options are needed. Peginterferon alpha-2a (40 kDa) is superior to conventional interferon alpha-2a in the treatment of chronic hepatitis C. This is the first report on peginterferon alpha-2a (40 kDa) ...

Discussions